Li Yuyang, Hong Fanzhen, Yu Zhigang
Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, China.
J Int Med Res. 2013 Jun;41(3):596-602. doi: 10.1177/0300060513485856. Epub 2013 May 21.
MicroRNA-206 (miR-206) is downregulated in many human malignancies, which correlates with tumour progression. This study characterized the contribution of miR-206 to the initiation and progression of human breast cancer.
Consecutive primary breast cancer patients who received radical resection were enrolled. Breast cancer tissue samples were obtained during surgery. MiR-206 levels in matched pairs of cancer tissue and normal adjacent tissue (NAT) samples were examined using quantitative reverse transcription-polymerase chain reaction. The relationship between miR-206 levels and clinicopathological characteristics and overall survival was also investigated.
In 128 patients with breast cancer, miR-206 was downregulated in 119 (93%) tumour tissue compared with their matched NAT samples. Decreased miR-206 was significantly associated with advanced clinical stage and lymph node metastasis. Univariate and multivariate Cox proportional hazard regression analysis revealed that a low miR-206 level was an unfavourable prognostic factor for overall survival, in patients with breast cancer.
This study indicated that miR-206 may be a good candidate as a novel prognostic indicator in breast cancer patients.
微小RNA-206(miR-206)在许多人类恶性肿瘤中表达下调,这与肿瘤进展相关。本研究旨在明确miR-206在人类乳腺癌发生和进展中的作用。
纳入接受根治性切除术的连续性原发性乳腺癌患者。手术过程中获取乳腺癌组织样本。采用定量逆转录-聚合酶链反应检测癌组织与配对的癌旁正常组织(NAT)样本中miR-206的水平。同时研究miR-206水平与临床病理特征及总生存期的关系。
在128例乳腺癌患者中,与配对的NAT样本相比,119例(93%)肿瘤组织中miR-206表达下调。miR-206降低与临床分期进展和淋巴结转移显著相关。单因素和多因素Cox比例风险回归分析显示,miR-206低水平是乳腺癌患者总生存期的不良预后因素。
本研究表明,miR-206可能是乳腺癌患者一种新型预后指标的良好候选者。